Scynexis (SCYX) Receives Daily Media Impact Score of 0.13

News coverage about Scynexis (NASDAQ:SCYX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Scynexis earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.0857059003343 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Get Scynexis alerts: Steady Activities: SCYNEXIS, Inc. (NASDAQ:SCYX), LPL Financial Holdings Inc. (NASDAQ:LPLA) (oracleexaminer.com) Do Analysts Think You Should Buy �� SCYNEXIS Inc (NASDAQ: SCYX) (stockspen.com) Notable Runner: SCYNEXIS, Inc. (SCYX) (nasdaqplace.com) Most Active Stocks Now: SCYNEXIS, Inc. (NASDAQ:SCYX), China Pharma Holdings, Inc. (NYSE:CPHI), Kala … (journalfinance.net) Overview on price to free cash flow: SCYNEXIS, Inc. (NASDAQ:SCYX), InfuSystem Holdings Inc. (NYSE:INFU) (stocksnewspoint.com)

Several research analysts have recently issued reports on the company. Roth Capital assumed coverage on Scynexis in a research note on Tuesday, May 8th. They set a “buy” rating and a $6.00 price target for the company. Seaport Global Securities assumed coverage on Scynexis in a research note on Tuesday, April 10th. They set a “buy” rating and a $4.00 price target for the company. Zacks Investment Research raised Scynexis from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, May 8th. HC Wainwright assumed coverage on Scynexis in a research note on Monday, May 7th. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine raised Scynexis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Scynexis currently has an average rating of “Buy” and an average target price of $4.45.

Scynexis traded up $0.20, hitting $1.63, during trading on Friday, MarketBeat reports. The stock had a trading volume of 2,272,811 shares, compared to its average volume of 378,384. Scynexis has a 1-year low of $1.05 and a 1-year high of $2.50. The company has a market capitalization of $66.75 million, a price-to-earnings ratio of -1.61 and a beta of 0.27. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.30.

Scynexis (NASDAQ:SCYX) last announced its earnings results on Tuesday, May 8th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.06. Scynexis had a negative net margin of 9,450.00% and a negative return on equity of 78.78%. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.10 million. research analysts predict that Scynexis will post -0.62 earnings per share for the current year.

In other news, CEO Marco Taglietti bought 100,000 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The stock was purchased at an average price of $1.69 per share, with a total value of $169,000.00. Following the purchase, the chief executive officer now owns 404,000 shares of the company’s stock, valued at approximately $682,760. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 141,500 shares of company stock valued at $237,155 in the last three months. 4.00% of the stock is currently owned by corporate insiders.

Scynexis Company Profile

SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.